Source: GlobalNewswire

Press Release: Karyopharm : LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm

NEW YORK, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Based on data from Karyopharm's latest SEC filings

Annual Revenue

Based on data from Karyopharm's latest SEC filings

Employees

Michael G. Kauffman's photo - Co-Founder & CEO of Karyopharm

Co-Founder & CEO

Michael G. Kauffman

CEO Approval Rating

68/100

Karyopharm researches and develops therapeutics for the treatment of cancer.

Karyopharm's headquarters is in Newton, Mass...
Read more